The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
PHASE2CompletedINTERVENTIONAL
Enrollment
11
Participants
Timeline
Start Date
January 31, 2014
Primary Completion Date
March 1, 2017
Study Completion Date
April 1, 2017
Conditions
Neuropathic Pain
Interventions
DRUG
N-acetyl-l-cysteine
1200 mg BID x 4 weeks
Trial Locations (1)
23298
Virginia Commonwealth University, Richmond
All Listed Sponsors
lead
Virginia Commonwealth University
OTHER
NCT01840345 - The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain | Biotech Hunter | Biotech Hunter